To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose

Launched by SINEW PHARMA INC. · Sep 27, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called TYNADOTE® to see how well it works and how safe it is for people who have taken too much acetaminophen, a common pain reliever. Acetaminophen overdose can cause serious liver damage, so finding effective treatments is very important. The trial is currently looking for participants who are hospitalized with an acetaminophen overdose, specifically those who have taken more than 150 mg/kg of the drug or have high levels of it in their blood.

To qualify for the study, participants must be at least 20 years old and able to give their consent to join. However, individuals with severe liver problems, certain allergies, or other serious health issues will not be eligible. If someone joins the trial, they will receive TYNADOTE® and be monitored closely to see how it helps their condition. This research is crucial for improving treatment options for acetaminophen overdose, and participating could contribute to better care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Poisoning and hospitalized patients taking acetaminophen.
• • Acute ingestion of more than 150 mg/kg or plasma concentration of Acetaminophen is above the treatment line on single acute acetaminophen overdose nomogram.
• • Male or female with age more than 20 years at Screening.
• • Ability and willingness to provide informed consent, adhere to the study visit schedule and complete all study assessments.
• Exclusion Criteria:
• • Subjects with Sequential Organ Failure Assessment (SOFA) Score higher than 12.
• • Subjects who fulfilled the King's College Hospital (KCH) Criteria for liver transplantation.
• • Subjects who was conscious disturbance.
• • History of allergic response(s) to N-acetylcysteine (NAC), mannitol, sucralose or related drugs.
• • Subject who was unable to take medicine by oral route.
• • Receiving any investigational drug within 30 days prior to first dosing.
• • Subject who had attacked asthma or bronchitis combined with medication therapy within six months prior to enrollment.
• • Donating greater than 150 mL of blood within two months prior to first dosing or donating plasma (e.g. plasmapheresis) within 14 days prior to first dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
• • Subject is pregnant or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test at baseline.
• • Anuria, pulmonary congestion, severe congestive heart failure, brain hemorrhage, or any conditions that in the opinion of the investigator may interfere with the evaluation of study objectives.
• • The combination of poisoning contains acetaminophen and other compound.
• • Body weight less than 50 kg.